NanoLogix Inc. (OTCBB:NNLX), an innovator in the rapid detection, identification and determination of antibiotic resistance and sensitivity of live bacteria, announces that William “Hank” Lewis has accepted the newly-created position of Vice President of Sales and Marketing for NanoLogix products. Mr. Lewis brings extensive sales and marketing expertise to the position, in a sales career spanning three decades, having most recently worked for CardioDx as Regional Sales Manager, preceded by roles as Regional Sales Manager with Myriad Genetics, Novartis Pharmaceuticals, and Knoll Pharmaceuticals for sales over multistate regions. In accepting the position, Mr. Lewis stated, “I am extremely excited to be part of Nanologix and work with the team to take our sales to the next level”. Mr. Lewis has begun his work with NanoLogix by representing the Company with other staff at the current ASM exhibition.

The Company also announces the promotion of Michelle Durkin to the position of Director of Laboratory Operations and New Product Development.

NanoLogix is currently attending and exhibiting at the American Society for Microbiology Annual Meeting (ASM) in Boston, MA. Interest in the Company’s existing products and emerging technology at the ASM during the first two days of the exhibition has been very strong. The Company can be visited at booth 134 in the Boston Convention Center’s Hall B, on Summer St. through 3 PM today. Information on the meeting can be found at: http://gm.asm.org/

Jonathan Faro, MD., of Woman’s Hospital of Texas in Houston, Is presenting a poster titled “Simultaneous Identification of Select Microbial Pathogens and Determination of Antimicrobial Resistance by a Unique Assay” in poster session 210, at display position 2564 in the Poster Hall of the ASM exhibition on 20 May. The technology referenced in the poster is NanoLogix’s patent-pending “N-Assay” Multiwell Microplate, a unique ELISA assay that ongoing research to date has shown enables detection and identification of bacteria and yeasts rapidly and with greater sensitivity than any other diagnostic currently available.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

For more information visit: http://www.nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.